Table 2.
Medication use during the MR-HIFU treatment of uterine fibroids
| Name, dosage, route | Average (number of patients (N) /percentage) | Range [min–max] | Conversion factor (gCO2/g) | CO2-emission (kg) |
|---|---|---|---|---|
| Propofol 2%, perfusor infusion | 392.6 mg (25, 100%) | 60.36–1000 mg | 21 | 0.0083 |
| Fentanyl 25–100 µg/mL | 162.0 µg (23, 92%) | 25–550 µg | 96 | > 0.000 |
| Lidocaine 2% | 17.2 mg (16, 64%) | 10–40 mg | 29 | 0.0005 |
| Carbetocine 100 µg/mL | 88.0 µg (22, 88%) | 0–100 µg | 340 | > 0.000 |
| Gadoteeracid 7.5 mmol/15 mL | 7.5 mmol (25, 100%) | 7.5 mmol | 340 | 0.0026 |
| Natriumchloride 0.9% perfusor infusion | 266.2 mg (25, 100%) | 116.25–450.00 mg | 200 | 0.053 |
| Paracetamol, 500 mg tablet | 1420.0 mg (24, 96%) | 1000–3000 mg | 7.8 | 0.011 |
| Diclofenac, 50 mg tablet | 90.0 mg (20, 80%) | 50–200 mg | 340 | 0.031 |
| Oxycodon short-acting, 10 mg meltingtablet | 10.8 mg (24, 96%) | 10–30 mg | 340 | 0.004 |
| Microlax, 5 mL sacheta | 4.4 mL (22, 88%) | 0–5 mL | x | x |
| Granisetron 1 mg/mL | 0.2 mg (5, 20%) | 0–1 mg | 340 | > 0.000 |
| Oxygen 2 L | 221.1 min (24, 96%) | 163–345 min | 2.1 | 0.016 |
| Buscopan 10 mg/0.5 mLb | 0.4 mg (1, 4%) | 0–10 mg | x | |
| Pantoprazol 40 mg tabletb | 1.5 mg (1, 4%) | 0–40 mg | x | |
| Atropine, 0.5 mg/mLb | > 0.0 mg (1, 4%) | 0–0.5 mg | x | |
| Dexamethason 4 mg/mLb | 0.2 mg (1, 4%) | 0–4 mg | x | |
| Alfentanil 0.25 mg/0.5 mLb | 0.1 mg (1, 4%) | 0–0.25 mg | x | |
| Total per patient | 0.125 ± 0.04 |
MR-HIFU Magnetic Resonance image-guided High-Intensity Focused Ultrasound, gCO2/g gram carbon dioxide per gram
aCombination medication, excluded from the analysis
bMedication applied to only one patient, excluded from the analysis